Article Details
Retrieved on: 2024-06-18 17:17:44
Tags for this article:
Click the tags to see associated articles and topics
Summary
Gracell Biotechnologies, acquired by AstraZeneca, is expanding its cell therapy production in China, enhancing AstraZeneca’s capabilities in cancer immunotherapy and autoimmune diseases, aligning with its strategic focus on the biotech sector.
Article found on: www.yicaiglobal.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here